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Neuropsychiatric disorders
in patient with end-of-life stage
of cancer disease — a case report
Abstract
Advanced cancer disease often results in many unpleasant physical and psychological symptoms.  They may
have an important impact on the patients’ quality of life. Acute psychotic disorders like cognitive failure, and
delirium in particular, are quite common in patients referred to oncologists and palliative care units. Here we
describe the case of a man, 63 years of age, with squamous cell lung cancer, treated for severe pain due to
bone metastases, who developed cognitive failure and delirium. We discuss delirium, its diagnosis and
treatment which may help the clinician to improve their skills.
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Introduction
Cognitive disorders are second most common
group of psychiatric symptoms in oncologic and
palliative care patients. The Diagnostic and Statisti-
cal Manual of Mental Disorders, Fourth edition (DSM-
IV) divides cognitive disorders into some sub-cate-
gories. One of them is: delirium, dementia, amnesic
and other cognitive disorders [1]. Prevalence of de-
lirium is increasing as the general population in-
cluding patients with cancer, live longer. Delirium
contributes to increased morbidity and mortality,
substantial treatment costs, and a lot of stress in
the family and professional carers. Diagnosis, as-
sessment and treatment of delirium is quite diffi-
cult and complicated because of imprecise concepts,
subtle, inconsistent, and overlapping symptoms, and
multiple causes.
Case report
A 63-years-old male patient was referred to Pal-
liative Care In-Patient Unit in January 2009 due to
persistent pain of left lower extremity and right
shoulder region. He was diagnosed with squamous
cell lung cancer in September 2007 and started sys-
temic treatment with four cycles of cisplatin, vi-
norelbine and fractionated radiotherapy. He was
well during all check ups in the clinic until January
2009. Few days before admission to the Palliative
Care Unit he had a fall. The X-ray showed extensive
metastatic deposits and bone losses in the left fe-
mur, but no fracture. The patient was treated con-
servatively and was administered a single dose of
90 mg Pamidronate IV. He became bedbound. On
admission to Palliative Care Unit he was commenced
on analgesics which reduced substantially his pain.
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The effective regime consisted of oxycodone SR 20
mg bid, oxycodone IR 5 mg prn for break-through
pain, ketoprofen 100 mg bid and gabapentin 100
mg tid. He was offered palliative radiotherapy, but
refused it. Unfortunately, a while later he devel-
oped chest infection and periodotal abscess neces-
sitating IV antibiotics and drainage. Drainage by
the maxillofacial surgeon was partially successful
and another session was planned in the future. Be-
cause in the same time patient’s pain, especially of
the right shoulder, has increased, dose of oxycodone
was increased to 25 mg bid, gabapentin 300 mg
tid, and two new drugs were added: paracetamol
500 mg tid and fluoxetine 20 mg once daily be-
cause of increasing psychological depression. This
approach resulted in general improvement. The lab-
oratory tests did not show significant abnormali-
ties. He was started with some gentle physiothera-
py. A couple of days later he felt unwell, weak and
sweating. His body temperature was 38.7∞C, and
pulse rate 110/min, BP was 90/60 mm Hg. There
were crepitations in the lower parts of the lungs.
The metastatic pneumonia with the focus in the
jaw suspected. The same day, during the physio-
therapeutic exercises, patient experienced severe,
stabbing, lancinating and excruciating pain of the
left leg. Clinically fracture of the femur was diag-
nosed and the leg was stabilized in a Brown’s de-
vice. SR oxycodone was switched to SR morphine
titrated up to 60 mg bid and dexamethazone 4 mg
once daily IV was added. Opioid switch was unfor-
tunately needed due to supply problems and tem-
porary lack of oxycodon in the setting. Gabapentin
and ketoprofen were continued. With occasional IR
morphine 20–40 mg prn the pain at rest was quite
well controlled. Later IV ketamine 30 mg was add-
ed to this regime. In the same time discrete cogni-
tive disorders like slight confusion with lucid inter-
vals were observed. The symptoms of cognitive fail-
ure exacerbated dramatically in a short time. The
patient was time and disorientated in time and
place, restless, anxious, very agitated which exacer-
bated the pain. Severe hypercalcaemia (12.1 mg/dL,
total calcium, ref. range 8.5–10.6 mg/dL) was diag-
nosed. At that stage acute delirium was diagnosed
and the patient was treated with 12.5 mg of levome-
promazine IV with stat dose of 5 mg midazolam IV,
continued 2 mg every 1 hour to dose 6mg. This
therapy, which was chose to achieve a bit more
sedation for a while, settled him for a period of 2
hours. Patient received an indwelling bladder cath-
eter. After that the patient was given IV Levome-
promazine 12.5 mg qid, i.v. midazolam 3 mg qid,
dexamethasone was discontinued. The patient was
settled, relatively lucid before he passed away two
days later.
Discussion
People often say that they fear more the dying
than being dead. Indeed, the quality of dying can
be challenged by the unrelieved symptoms, both
physical and psychological. On the other hand man-
agement of many mental disorders like delirium,
depression, anxiety, suicidal ideation, may be chal-
lenging even for a most experienced palliative med-
icine specialists [2, 3].
Cognitive failure is unfortunately very common
in patients with advanced stage of chronic disease.
The prevalence of delirium is ranging from 25 to
40% of cancer patients, growing up enormously to
almost 85% of terminal cancer patients [2, 4–6].
Although not much is known about the mechanisms
of this disorder, observed symptoms suggest multi-
focal malfunction of different brain regions. Deliri-
um has been defined as non-specific cerebral dys-
function characterized by concurrent disturbances
of level of consciousness, attention, thinking, per-
ception, memory, psychomotor behaviour, emotion
and the sleep-wake cycle [7]. Among clinical fea-
tures of delirium one can find acute onset, confu-
sion, disorientation (in time, place and/or person),
distractibility, psychomotor agitation or retardation,
illusions (misperceptions) and hallucinations (usu-
ally visual), delusions (especially with paranoid
themes), fear and anxiety, autonomic dysfunctions,
diurnal variation (worse at night and early morning,
with lucid intervals especially during the day). Delir-
ium is being divided into three sub-types, based on
arousal disturbances and psychomotor behaviour,
which include “hyperactive”, “hypoactive” and
“mixed” sub-types. Most common are hypoactive
and mixed sub-types, but hyperactive delirium is
the most feared one and one the most clinicians are
familiar with [8]. Early signs of delirium may be
misdiagnosed as depression, dementia, fear, anxi-
ety, anger or manic episode [9]. The most common
differential diagnostic issue is whether the patient
actually has delirium or preexistent dementia, which
are both the cognitive disorders. Dementia appears
in relatively alert persons with little or no clouding
of consciousness. The onset of symptoms is more
chronic, and one’s sleep-wake cycle seems less im-
paired. Most prominent in dementia are difficulties
in short and long-term memory, impaired judge-
ment and abstract thinking, disturbances of higher
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cortical functions (aphasia, apraxia). Delirium, in
contrast to dementia, is being considered as revers-
ible even in patients with advanced chronic disease,
although it may not be fully reversible in terminally
ill patients who develop delirium in the last days or
hours of  their life (terminal delirium). This is due to
multiple organs irreversible failure [2, 10].
The standard approach to the managing deliri-
um includes searching for underlying causes, cor-
rection of these factors, and management of the
symptoms of delirium. In the terminally ill patients,
whatsoever, who develop delirium in last days of
life, the management of this disorder is quite unique,
presenting a number of dilemmas, and desired clin-
ical outcome may be significantly altered by the
dying process. There is an ongoing debate as to the
appropriate extent of diagnostic evaluation that
should be pursued in a dying patient with terminal
delirium. Most clinicians would undertake diagnos-
tic procedures only when a suspected aetiology can
be identified easily, with minimal use of invasive
procedures, and treated effectively with simple in-
terventions that carry minimal risk and burden to
the patient. Most often, however, the aetiology of
terminal delirium is multifactorial or remains ob-
scure. In patients with advanced cancer, delirium
may be due to both direct effect of disease on cen-
tral nervous system (primary or metastatic tumours)
and indirect effects of cancer or treatment on the
CNS. These indirect effects may be caused by meta-
bolic disturbances: hypoxia, hypercapnia, hypo- or
hyperglycaemia, electrolyte disturbances (including
hypercalcaemia), impaired liver and kidney functions,
infections, drugs (CNS depressants, gluco-corticos-
teroids, sympathomimetics, anticholinergics, opio-
ids, benzodiazepines), chemo and radiotherapy, but
also uncontrolled pain [3, 11–15].
In symptomatic treatment one can use pharma-
cologic and non-pharmacologic interventions. It is
important to provide quiet, well-lit room, filled with
familiar objects, with calendar and clock being visi-
ble. The presence of the family cannot be underesti-
mated [16]. These interventions are important but
frequently insufficient and needs to be accompa-
nied by appropriate pharmacological treatment. In
delirium the drugs of choice in the treatment of
delirium are antipsychotics (haloperidol, chlorpro-
mazine, levomepromazine, thioridazine). Atypical
antipsychotics (olanzapine, risperidone, quetiapine)
are effective but not always available in injectable
formulations. They are usually seen as alternatives
in case of extrapyramidal side effects or tardive dys-
kinesia caused by the first line drugs. Although the
aim of therapy is to diminish agitation, to clear
sensorium and improve cognition in the delirious
patient, this is not always possible in the terminally
ill and dying patients. Sometimes the symptoms
can be controlled only by decreasing of conscious-
ness and sedation. The latter can be achieved by
addition of benzodiazepines (lorazepam, mida-
zolam) [2, 5, 13–15, 17].
In our case the underlying aetiology of delirium
was clearly multifactorial. Among the factors that
certainly contributed to delirium was: pneumonia,
severe pain, opioids and steroids, as well as hyper-
calcaemia and possibly hepatic failure. Due to this
advanced disease phase, it was decided to aban-
don aggressive treatment with IV antibiotics and
bisphosphonates, as well as aggressive treatment
of metabolic abnormalities. The analgesic drugs were
continued, while the corticosteroids were with-
drawn. The antipsychotic drug, together with short
acting benzodiazepine, helped to settle agitation.
For a while the patient was lucid which was impor-
tant to the family.  The family was all the time
informed about the developments and was partici-
pating in decision making truly representing pa-
tient’s interests. Both patient and the family fully
accepted proposed therapy and the moment when
the patient needed to be sedated. With this agree-
ment the therapy was continued till the end. In that
way the best possible quality of dying was achieved.
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